相关实验视频

Updated: Jun 24, 2026

A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice

A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice

Published on: November 2, 2019

准胰岛素类生长因子1受体限制了小鼠中二次淋巴的发展和严重程度

Yinan Yuan^1,2, Sidney M Levy^2,3,4, Yong Qiang Yeo²

¹O'Brien Institute Department, St Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.

|March 10, 2025

概括

胰岛素类生长因子 (IGF) 信号驱动在二次淋巴中淋巴血管扩大. 用林西替尼布抑制IGF1受体可以减少胀和淋巴重塑,这表明了新的治疗点.

科学领域:

淋巴生物学淋巴生物学
血管改造是指进行血管改造.
疾病的分子机制.

背景情况:

二次性淋巴包括由于淋巴功能障碍而导致的慢性组织胀.
小淋巴细胞的病态扩大是关键特征,但其分子驱动因素尚不清楚.
胰岛素类生长因子 (IGF) 信号传递促进淋巴细胞重塑.

研究的目的:

研究二次淋巴瘤中淋巴重塑的基础分子机制.
在淋巴的小鼠模型中评估向IGF信号的治疗潜力.

主要方法:

二次性淋巴的外科小鼠模型.
全基因组微阵列分析以确定差异表达的基因.
使用林西替尼的IGF1受体 (IGF1R) 的药理抑制.

主要成果:

胰岛素样生长因子结合蛋白5 (IGFBP5) 转录在淋巴瘤组织中显著下调.
林西替尼治疗限制了小的淋巴扩大,并减少了淋巴发育期间的组织胀.
林西替尼抑制了IGF1R驱动的巨细胞的血管内皮生长因子-C (VEGF-C) 合成.
林西替尼在慢性淋巴 edem 模型中显著减少胀.

结论:

IGF信号传递,特别是通过IGF1R,在二次淋巴中淋巴重塑和胀中发挥着关键作用.
用林西提尼布向IGF1R表明了治疗淋巴的治疗潜力.
IGF信号传递代表了对二次淋巴的有前途的治疗标.

关键词:

细胞生物学细胞生物学病理生理学病理生理学

更多相关视频

Blocking Lymph Flow by Suturing Afferent Lymphatic Vessels in Mice

Blocking Lymph Flow by Suturing Afferent Lymphatic Vessels in Mice

Published on: May 14, 2020

A Murine Tail Lymphedema Model

A Murine Tail Lymphedema Model

Published on: February 10, 2021

相关概念视频

Cell Specific Gene Expression

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...